About Quellis Biosciences
Quellis Biosciences is a company based in Boston (United States) founded in 2017 by Vahe Bedian and Jonathan Violin was acquired by Astria in January 2021.. Quellis Biosciences has raised $17 million across 2 funding rounds from investors including Astria Therapeutics and Xontogeny. Quellis Biosciences operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Boston, United States
- Founders Vahe Bedian, Jonathan Violin
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17 M (USD)
in 2 rounds
-
Latest Funding Round
$17 M (USD), Series A
Dec 10, 2019
-
Investors
Astria Therapeutics
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Astria
(Jan 29, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Quellis Biosciences
Quellis Biosciences has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $17.0M
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2019 | Amount | Series A - Quellis Biosciences | Valuation |
investors |
|
| Nov, 2017 | Amount | Seed - Quellis Biosciences | Valuation | Xontogeny |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Quellis Biosciences
Quellis Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Astria Therapeutics and Xontogeny. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Founded Year | Domain | Location | |
|
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Quellis Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Quellis Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Quellis Biosciences Comparisons
Competitors of Quellis Biosciences
Quellis Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Quellis Biosciences
Frequently Asked Questions about Quellis Biosciences
When was Quellis Biosciences founded?
Quellis Biosciences was founded in 2017.
Where is Quellis Biosciences located?
Quellis Biosciences is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Quellis Biosciences a funded company?
Quellis Biosciences is a funded company, having raised a total of $17M across 2 funding rounds to date.
What does Quellis Biosciences do?
Quellis Biosciences was established in 2017 in Boston, United States, within the biotechnology sector. Monoclonal antibodies targeting rare diseases are developed and refined. Xtend technology is employed to extend antibody half-life and minimize dosing frequency. Focus is placed on antibody-based drug development, with operations conducted from the companys location in the United States.
Who are the top competitors of Quellis Biosciences?
Quellis Biosciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Who are Quellis Biosciences's investors?
Quellis Biosciences has 2 investors. Key investors include Astria Therapeutics, and Xontogeny.